{"filing":{"accession_number":"0001193125-26-253506","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"d95782d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/d95782d8k.htm"},"events":[{"id":7465,"run_id":6561,"accession_number":"0001193125-26-253506","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.82,"summary":"Jaguar Health issued 64,668 shares of common stock in two privately negotiated exchange transactions with Streeterville Capital in exchange for preferred stock, relying on Section 3(a)(9) exemption. This dilutive equity issuance materially affects shareholder ownership and voting power.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3578,"accession_number":"0001193125-26-253506","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Jaguar Health issued 64,668 shares of common stock (31,958 + 32,710) in two privately negotiated exchange transactions with Streeterville Capital in exchange for preferred stock. This represents a dilutive issuance of equity securities. While technically an exchange rather than a pure cash raise, the substance is the issuance of a material quantity of common stock that would dilute existing shareholders, which is material to investors assessing ownership and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:39.186775+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3579,"accession_number":"0001193125-26-253506","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses unregistered issuance of equity securities (First Exchange Shares and Second Exchange Shares) relying on Section 3(a)(9) exemption. This is a dilutive equity issuance that would materially affect shareholder ownership and is a key indicator of capital-raising activity, particularly relevant for smaller-cap companies like Jaguar Health.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:39.186775+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":7466,"run_id":6561,"accession_number":"0001193125-26-253506","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"summary":"The company adjourned its 2026 Annual Meeting of Stockholders from June 2 to June 8, 2026 to allow stockholders time to review a supplemental proxy statement filed on May 29, 2026. The substance of the supplemental information is not disclosed in this filing.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3580,"accession_number":"0001193125-26-253506","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The disclosure announces an adjournment of the 2026 Annual Meeting of Stockholders from June 2 to June 8, 2026 to allow stockholders time to review a supplemental proxy statement filed on May 29, 2026. While the adjournment itself is a procedural matter, the underlying reason—provision of supplemental information to stockholders—suggests potential material developments. However, the filing does not disclose the substance of the supplemental information, making it difficult to assess materiality. This is primarily a routine administrative disclosure regarding meeting logistics rather than a substantive material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:39.186775+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3578,"accession_number":"0001193125-26-253506","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Jaguar Health issued 64,668 shares of common stock (31,958 + 32,710) in two privately negotiated exchange transactions with Streeterville Capital in exchange for preferred stock. This represents a dilutive issuance of equity securities. While technically an exchange rather than a pure cash raise, the substance is the issuance of a material quantity of common stock that would dilute existing shareholders, which is material to investors assessing ownership and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:39.186775+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-02"},{"id":3579,"accession_number":"0001193125-26-253506","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses unregistered issuance of equity securities (First Exchange Shares and Second Exchange Shares) relying on Section 3(a)(9) exemption. This is a dilutive equity issuance that would materially affect shareholder ownership and is a key indicator of capital-raising activity, particularly relevant for smaller-cap companies like Jaguar Health.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:39.186775+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-02"},{"id":3580,"accession_number":"0001193125-26-253506","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The disclosure announces an adjournment of the 2026 Annual Meeting of Stockholders from June 2 to June 8, 2026 to allow stockholders time to review a supplemental proxy statement filed on May 29, 2026. While the adjournment itself is a procedural matter, the underlying reason—provision of supplemental information to stockholders—suggests potential material developments. However, the filing does not disclose the substance of the supplemental information, making it difficult to assess materiality. This is primarily a routine administrative disclosure regarding meeting logistics rather than a substantive material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:39.186775+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-02"}]}